Oral Health


Periodontitis is a chronic inflammatory disease in the tissues and bones that support teeth. This condition is fairly common, affecting 10-15% adults worldwide. When untreated, the disease progresses deeper into the tissue, causing eventual loss of teeth. Ironically, patients have only few treatment options and mostly rely on uncomfortable dental procedures combined with antibiotics. GlycoMira is developing novel anti-inflammatory and anti-bacterial therapeutics to treat and prevent periodontitis. Please contact us for more information.

Oral Mucositis

Oral mucositis is a seriously painful condition that many cancer patients experience during chemoradiation therapy. Patients experience agonizing pain in the mouth, making it difficult to eat and drink. Treatment options for oral mucositis are extremely limited. GlycoMira is developing therapeutics to treat this adverse effects in cancer patients. Our technology provides countermeasures to prevent inflammation in healthy tissues caused by chemoradiation. Please contact us for more information.


  • A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis (2016). More info.
  • Prevention of Anti-microbial Peptide LL-37-Induced Apoptosis and ATP Release in the Urinary Bladder by a Modified Glycosaminoglycan (2013) More info.
  • Physiologic Relevance of LL-37 Induced Bladder Inflammation and Mast Cells (2013). More info.
  • Novel Sulfated Polysaccharides Disrupt Cathelicidins, Inhibit RAGE and Reduce Cutaneous Inflammation in a Mouse Model of Rosacea (2011). More info
  • Low-Anticoagulant Heparins in the Treatment of Metastasis, Research on Melanoma – A Glimpse into Current Directions and Future Trends (2011). More info.
  • A murine model of inflammatory bladder disease: cathelicidin peptide induced bladder inflammation and treatment with sulfated polysaccharides (2011). More info.